CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners
CENTOGENE Announces Voting Results of Extraordinary General Meeting
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners
Centogene Adjusts Leadership Resignation Dates
Centogene Shifts Ex-CFO to Consultant Role
Centogene Delays Board Members’ Resignation
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson?s Disease in The Lancet Neurology
CENTOGENE Receives Delisting Notice From Nasdaq
CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson?s Disease Cases Are Linked to Genetic Factors
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
